» Articles » PMID: 20433428

The Metabolic Syndrome in Patients on Peritoneal Dialysis: Prevalence and Influence on Cardiovascular Morbidity

Overview
Specialty General Medicine
Date 2010 May 4
PMID 20433428
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolic syndrome (MS) is a multi-factorial disorder which includes a main risk factors associated with the development of cardiovascular, neurologic, renal and endocrine diseases, especially type 2 diabetes. This study has been conducted to estimate the prevalence of the MS in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and its association with cardiovascular morbidity. The study included 37 patients (25 type 2 diabetic patients and 12 non-diabetic patients), who had been on peritoneal dialysis for > 3 months. At the beginning of CAPD treatment (baseline) and at the end of follow-up, we measured: body mass index (BMI), blood pressure, fasting blood glucose, triglycerides and high-density lipoprotein cholesterol (HDLC) and defined the prevalence of the MS using the modified National Cholesterol Education Program (NCEP; Adult Treatment Panel III) for peritoneal dialysis patients. The overall prevalence of the MS was 89.2%. The metabolic syndrome was estimated in all (100%) type 2 diabetic patients (vs. 60% patients on the beginning of CAPD treatment). In non-diabetic peritoneal patients, the MS was estimated in 50% cases, according to 33.3% at the beginning CAPD treatment. Development of the MS was significantly higher in the type 2 diabetic patients in compared with non-diabetic patients until the end of follow-up examination (p=0.0005). The prevalence of LVH in type 2 diabetic patients with the MS was significantly higher (p=0.002) than in non-diabetic peritoneal patients with the MS. We didn't found statistical significantly difference in the prevalence of ischemic heart disease between this two category of peritoneal dialysis patients (p=0.076). The results indicate that the metabolic syndrome is presented in high percentage in peritoneal dialysis patients, and it's also important risk factor of high cardiovascular morbidity rate in these patients, especially in type 2 diabetic patients.

Citing Articles

Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications.

Szeto C, Kwan B, Chow K, Leung C, Cheng M, Law M Clin J Am Soc Nephrol. 2014; 9(4):779-87.

PMID: 24458080 PMC: 3974356. DOI: 10.2215/CJN.06620613.


High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.

Wen Y, Guo Q, Yang X, Wu X, Feng S, Tan J Perit Dial Int. 2013; 35(1):70-7.

PMID: 24293666 PMC: 4335930. DOI: 10.3747/pdi.2013.00083.

References
1.
Lindsay R, Howard B . Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep. 2004; 4(1):63-8. DOI: 10.1007/s11892-004-0013-9. View

2.
Johnson D, Armstrong K, Campbell S, Mudge D, Hawley C, Coombes J . Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007; 12(4):391-8. DOI: 10.1111/j.1440-1797.2007.00804.x. View

3.
Bestermann W, Houston M, Basile J, Egan B, Ferrario C, Lackland D . Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of.... Am J Med Sci. 2005; 329(6):292-305. DOI: 10.1097/00000441-200506000-00009. View

4.
McDonald S, Collins J, Johnson D . Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol. 2003; 14(11):2894-901. DOI: 10.1097/01.asn.0000091587.55159.5f. View

5.
Dekker J, Girman C, Rhodes T, Nijpels G, Stehouwer C, Bouter L . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112(5):666-73. DOI: 10.1161/CIRCULATIONAHA.104.516948. View